Sign In
Buy SNWV
SANUWAVE Health Earnings Calls
| Release date | May 12, 2026 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.170 |
| EPS Surprise | -21.43% |
| Revenue estimate | 9.6M |
| Revenue actual | 9.619M |
| Revenue Surprise | 0.198% |
| Release date | Mar 26, 2026 |
| EPS estimate | $0.170 |
| EPS actual | $0.0300 |
| EPS Surprise | -82.35% |
| Revenue estimate | 13.25M |
| Revenue actual | 13.394M |
| Revenue Surprise | 1.09% |
| Release date | Nov 07, 2025 |
| EPS estimate | $0.320 |
| EPS actual | $0.460 |
| EPS Surprise | 43.75% |
| Revenue estimate | 13.226M |
| Revenue actual | 11.451M |
| Revenue Surprise | -13.42% |
| Release date | Aug 08, 2025 |
| EPS estimate | -$0.0900 |
| EPS actual | $0.0100 |
| EPS Surprise | 111.11% |
| Revenue estimate | 12.523M |
| Revenue actual | 10.164M |
| Revenue Surprise | -18.84% |
Last 4 Quarters for SANUWAVE Health
Below you can see how SNWV performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 08, 2025 |
| Price on release | $39.76 |
| EPS estimate | -$0.0900 |
| EPS actual | $0.0100 |
| EPS surprise | 111.11% |
| Date | Price |
|---|---|
| Aug 04, 2025 | $35.49 |
| Aug 05, 2025 | $35.00 |
| Aug 06, 2025 | $35.23 |
| Aug 07, 2025 | $34.32 |
| Aug 08, 2025 | $39.76 |
| Aug 11, 2025 | $42.74 |
| Aug 12, 2025 | $41.70 |
| Aug 13, 2025 | $39.88 |
| Aug 14, 2025 | $37.78 |
| 4 days before | 12.03% |
| 4 days after | -4.98% |
| On release day | 7.49% |
| Change in period | 6.45% |
| Release date | Nov 07, 2025 |
| Price on release | $31.08 |
| EPS estimate | $0.320 |
| EPS actual | $0.460 |
| EPS surprise | 43.75% |
| Date | Price |
|---|---|
| Nov 03, 2025 | $27.42 |
| Nov 04, 2025 | $27.50 |
| Nov 05, 2025 | $26.81 |
| Nov 06, 2025 | $26.41 |
| Nov 07, 2025 | $31.08 |
| Nov 10, 2025 | $34.26 |
| Nov 11, 2025 | $35.34 |
| Nov 12, 2025 | $33.35 |
| Nov 13, 2025 | $33.56 |
| 4 days before | 13.35% |
| 4 days after | 7.98% |
| On release day | 10.23% |
| Change in period | 22.39% |
| Release date | Mar 26, 2026 |
| Price on release | $18.85 |
| EPS estimate | $0.170 |
| EPS actual | $0.0300 |
| EPS surprise | -82.35% |
| Date | Price |
|---|---|
| Mar 20, 2026 | $20.20 |
| Mar 23, 2026 | $20.49 |
| Mar 24, 2026 | $20.18 |
| Mar 25, 2026 | $19.93 |
| Mar 26, 2026 | $18.85 |
| Mar 27, 2026 | $18.61 |
| Mar 30, 2026 | $17.39 |
| Mar 31, 2026 | $17.29 |
| Apr 01, 2026 | $16.85 |
| 4 days before | -6.68% |
| 4 days after | -10.61% |
| On release day | -1.27% |
| Change in period | -16.58% |
| Release date | May 12, 2026 |
| Price on release | $16.04 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.170 |
| EPS surprise | -21.43% |
| Date | Price |
|---|---|
| May 06, 2026 | $15.92 |
| May 07, 2026 | $16.65 |
| May 08, 2026 | $15.57 |
| May 11, 2026 | $16.00 |
| May 12, 2026 | $16.04 |
| May 13, 2026 | $18.94 |
| May 14, 2026 | $17.07 |
| May 15, 2026 | $16.85 |
| May 18, 2026 | $16.86 |
| 4 days before | 0.754% |
| 4 days after | 5.11% |
| On release day | 18.08% |
| Change in period | 5.90% |
SANUWAVE Health Earnings Call Transcript Summary of Q1 2026
SANUWAVE reported a mixed but constructive Q1 2026: revenue was a company-record Q1 of $9.6M (up 3% YoY) with consumables utilization up 22% YoY and sequential applicator unit sales at an all-time high. The quarter began with a market-wide pause following CMS reimbursement changes, but management says the market is thawing, with active systems increasing by 90 to 1,382 and improving monthly trends across Q1. Gross margin contracted to 77.3% due to a higher mix of reseller (wholesale) sales. Operating loss was $1.1M and net loss $1.4M (improved vs. prior year primarily from nonrecurring derivative losses in 2025), adjusted EBITDA was positive $1.1M. Cash was $10.8M at quarter end. Management reiterated full-year revenue guidance of $51M–$55M and provided Q2 guidance of 10%–15% YoY growth ($11.1M–$11.6M), citing seasonal tailwinds, several large account evaluations, and growing traction in hospitals, wound centers, long-term care and mobile wound care. Headcount, R&D and one-time remediation costs increased operating expenses; management expects operating leverage to improve as revenue scales.
